Strides puts best biopharma foot forward into Malaysia
This article was originally published in Scrip
Malaysia continues to draw Indian pharma manufacturing interest, offering attractive tax breaks and a well-developed infrastructure to companies wanting to develop their business in the Asian region. Strides Arocolab is the latest Indian firm to unveil plans to set up a biopharmaceuticals unit in the Malaysian biotech park, Bio-XCell.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.